Literature DB >> 24273680

The Complex Ethics of First In Human Stem Cell Clinical Trials.

Mark Yarborough1, Teresa Tempkin, Jan Nolta, Nanette Joyce.   

Abstract

Entities:  

Year:  2012        PMID： 24273680      PMCID： PMC3835337          DOI： 10.1080/21507740.2012.675010

Source DB:  PubMed          Journal:  AJOB Neurosci        ISSN： 2150-7759


× No keyword cloud information.
  11 in total

Review 1.  Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.

Authors:  Todd Meyerrose; Scott Olson; Suzanne Pontow; Stefanos Kalomoiris; Yunjoon Jung; Geralyn Annett; Gerhard Bauer; Jan A Nolta
Journal:  Adv Drug Deliv Rev       Date:  2010-10-13       Impact factor: 15.470

Review 2.  Mesenchymal stromal cells for graft-versus-host disease.

Authors:  Jakub Tolar; Pierre Villeneuve; Armand Keating
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

3.  Public trust and research a decade later: what have we learned since Jesse Gelsinger's death?

Authors:  Mark Yarborough; Richard R Sharp
Journal:  Mol Genet Metab       Date:  2009-02-20       Impact factor: 4.797

Review 4.  Cell-based interventions for neurologic conditions: ethical challenges for early human trials.

Authors:  D J H Mathews; J Sugarman; H Bok; D M Blass; J T Coyle; P Duggan; J Finkel; H T Greely; A Hillis; A Hoke; R Johnson; M Johnston; J Kahn; D Kerr; J Kurtzberg; S M Liao; J W McDonald; G McKhann; K B Nelson; M Rao; A Regenberg; A W Siegel; K Smith; D Solter; H Song; A Vescovi; W Young; J D Gearhart; R Faden
Journal:  Neurology       Date:  2008-05-07       Impact factor: 9.910

5.  Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.

Authors:  Scott D Olson; Amal Kambal; Kari Pollock; Gaela-Marie Mitchell; Heather Stewart; Stefanos Kalomoiris; Whitney Cary; Catherine Nacey; Karen Pepper; Jan A Nolta
Journal:  Mol Cell Neurosci       Date:  2011-12-08       Impact factor: 4.314

Review 6.  Mesenchymal stem cells for the treatment of neurodegenerative disease.

Authors:  Nanette Joyce; Geralyn Annett; Louisa Wirthlin; Scott Olson; Gerhard Bauer; Jan A Nolta
Journal:  Regen Med       Date:  2010-11       Impact factor: 3.806

7.  Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease.

Authors:  Nicholas D Dey; Matthew C Bombard; Bartholomew P Roland; Stacy Davidson; Ming Lu; Julien Rossignol; Michael I Sandstrom; Reid L Skeel; Laurent Lescaudron; Gary L Dunbar
Journal:  Behav Brain Res       Date:  2010-05-21       Impact factor: 3.332

8.  A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury.

Authors:  Z-X Zhang; L-X Guan; K Zhang; Q Zhang; L-J Dai
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

Review 9.  Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease.

Authors:  Scott D Olson; Kari Pollock; Amal Kambal; Whitney Cary; Gaela-Marie Mitchell; Jeremy Tempkin; Heather Stewart; Jeannine McGee; Gerhard Bauer; Hyun Sook Kim; Teresa Tempkin; Vicki Wheelock; Geralyn Annett; Gary Dunbar; Jan A Nolta
Journal:  Mol Neurobiol       Date:  2011-12-09       Impact factor: 5.590

Review 10.  Why are MSCs therapeutic? New data: new insight.

Authors:  A I Caplan
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996
View more
  1 in total

1.  One Size Fits All?: Ethical Considerations for Examining Efficacy in First-in-Human Pluripotent Stem Cell Studies.

Authors:  Michelle Gjl Habets; Johannes Jm van Delden; Sophie L Niemansburg; Harold L Atkins; Annelien L Bredenoord
Journal:  Mol Ther       Date:  2016-12       Impact factor: 11.454
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.